• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Advancing inclusive research calculator for oncology disease areas: A resource to support the development of enrollment targets in diversity action plans for industry sponsors.推进肿瘤疾病领域的包容性研究计算器:一种为行业赞助商的多样性行动计划制定入组目标提供支持的资源。
PLoS One. 2024 Dec 19;19(12):e0315283. doi: 10.1371/journal.pone.0315283. eCollection 2024.
2
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
3
Correction: Advancing inclusive research calculator for oncology disease areas: A resource to support the development of enrollment targets in diversity action plans for industry sponsors.更正:推进肿瘤疾病领域的包容性研究计算器:一种支持行业赞助商制定多样性行动计划中入组目标的资源。
PLoS One. 2025 May 12;20(5):e0324115. doi: 10.1371/journal.pone.0324115. eCollection 2025.
4
Assessment of gender representation in clinical trials leading to FDA approval for oncology therapeutics between 2014 and 2019: A systematic review-based cohort study.评估 2014 年至 2019 年间导致 FDA 批准肿瘤治疗药物的临床试验中的性别代表性:基于系统评价的队列研究。
Cancer. 2021 Sep 1;127(17):3156-3162. doi: 10.1002/cncr.33533. Epub 2021 Jun 23.
5
The project data sphere initiative: accelerating cancer research by sharing data.项目数据领域计划:通过数据共享加速癌症研究
Oncologist. 2015 May;20(5):464-e20. doi: 10.1634/theoncologist.2014-0431. Epub 2015 Apr 15.
6
Navigating the Regulatory Landscape to Develop Pediatric Oncology Drugs: Expert Opinion Recommendations.儿科肿瘤药物研发的监管格局:专家意见建议
Paediatr Drugs. 2021 Jul;23(4):381-394. doi: 10.1007/s40272-021-00455-1. Epub 2021 Jun 26.
7
Advancing Inclusive Research (AIR) Site Alliance: Facilitating the inclusion of historically underrepresented people in oncology and ophthalmology clinical research.推进包容性研究(AIR)站点联盟:促进将历史上代表性不足的人群纳入肿瘤学和眼科学临床研究。
Contemp Clin Trials. 2024 Feb;137:107416. doi: 10.1016/j.cct.2023.107416. Epub 2023 Dec 16.
8
American Society of Clinical Oncology policy statement: oversight of clinical research.美国临床肿瘤学会政策声明:临床研究监督
J Clin Oncol. 2003 Jun 15;21(12):2377-86. doi: 10.1200/JCO.2003.04.026. Epub 2003 Apr 29.
9
MarkVCID cerebral small vessel consortium: I. Enrollment, clinical, fluid protocols.马克 VCID 脑小血管联盟:一、入组、临床、液体方案。
Alzheimers Dement. 2021 Apr;17(4):704-715. doi: 10.1002/alz.12215. Epub 2021 Jan 21.
10
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.

引用本文的文献

1
Correction: Advancing inclusive research calculator for oncology disease areas: A resource to support the development of enrollment targets in diversity action plans for industry sponsors.更正:推进肿瘤疾病领域的包容性研究计算器:一种支持行业赞助商制定多样性行动计划中入组目标的资源。
PLoS One. 2025 May 12;20(5):e0324115. doi: 10.1371/journal.pone.0324115. eCollection 2025.

本文引用的文献

1
Cause-specific mortality by county, race, and ethnicity in the USA, 2000-19: a systematic analysis of health disparities.美国 2000-19 年按县、种族和民族划分的特定原因死亡率:健康差距的系统分析。
Lancet. 2023 Sep 23;402(10407):1065-1082. doi: 10.1016/S0140-6736(23)01088-7. Epub 2023 Aug 3.
2
Interpreting cancer incidence trends: challenges due to the COVID-19 pandemic.解读癌症发病趋势:新冠疫情带来的挑战。
J Natl Cancer Inst. 2023 Sep 7;115(9):1109-1111. doi: 10.1093/jnci/djad086.
3
Clinical Trial Diversity in Oncology: FDA Takes Action with Post-Marketing Requirements or Commitments.肿瘤学临床试验的多样性:FDA 采取行动,要求或承诺进行上市后要求。
Oncologist. 2022 Dec 9;27(12):993-997. doi: 10.1093/oncolo/oyac228.
4
The history and use of cancer registry data by public health cancer control programs in the United States.美国公共卫生癌症控制项目对癌症登记数据的历史及应用情况。
Cancer. 2017 Dec 15;123 Suppl 24(Suppl 24):4969-4976. doi: 10.1002/cncr.30905.
5
Surveillance for Cancer Incidence and Mortality - United States, 2012.癌症发病率和死亡率监测-美国,2012 年。
MMWR Morb Mortal Wkly Rep. 2016 Oct 14;63(55):17-58. doi: 10.15585/mmwr.mm6355a4.
6
Validity of Race, Ethnicity, and National Origin in Population-based Cancer Registries and Rapid Case Ascertainment Enhanced With a Spanish Surname List.基于人群的癌症登记中种族、族裔和国籍的有效性以及通过西班牙姓氏列表增强快速病例确定
Med Care. 2016 Jan;54(1):e1-8. doi: 10.1097/MLR.0b013e3182a30350.
7
Efficient interval estimation for age-adjusted cancer rates.年龄调整癌症发病率的有效区间估计。
Stat Methods Med Res. 2006 Dec;15(6):547-69. doi: 10.1177/0962280206070621.
8
Quality of race, Hispanic ethnicity, and immigrant status in population-based cancer registry data: implications for health disparity studies.基于人群的癌症登记数据中的种族、西班牙裔族裔和移民身份质量:对健康差异研究的影响。
Cancer Causes Control. 2007 Mar;18(2):177-87. doi: 10.1007/s10552-006-0089-4. Epub 2007 Jan 11.
9
Misclassification of race/ethnicity in a population-based cancer registry (United States).基于人群的癌症登记处(美国)中种族/族裔的错误分类。
Cancer Causes Control. 2006 Aug;17(6):771-81. doi: 10.1007/s10552-006-0013-y.
10
Hospital policy and practice regarding the collection of data on race, ethnicity, and birthplace.医院关于收集种族、族裔和出生地数据的政策与实践。
Am J Public Health. 2003 Oct;93(10):1685-8. doi: 10.2105/ajph.93.10.1685.

推进肿瘤疾病领域的包容性研究计算器:一种为行业赞助商的多样性行动计划制定入组目标提供支持的资源。

Advancing inclusive research calculator for oncology disease areas: A resource to support the development of enrollment targets in diversity action plans for industry sponsors.

作者信息

Press David J, James Spencer L, Jolain Bruno, Richie Nicole

机构信息

A Member of the Roche Group, Genentech, South San Francisco, California, United States of America.

Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina, United States of America.

出版信息

PLoS One. 2024 Dec 19;19(12):e0315283. doi: 10.1371/journal.pone.0315283. eCollection 2024.

DOI:10.1371/journal.pone.0315283
PMID:39700219
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11658589/
Abstract

BACKGROUND

The Food and Drug Omnibus Report Act, signed into law in 2022, requires industry sponsors to include diversity action plans in clinical study protocols. Defining reliable methodology for measures and benchmarks is critical to ensuring adequate and consistent representation of historically underrepresented patient populations in clinical trials.

METHODS

We provide an Advancing Inclusive Research (AIR) Calculator, summary tables, and data query bank to support target setting for the development of diversity action plans and to take steps toward defining enrollment standards. The AIR Calculator uses data from the US Cancer Statistics database, which covers 100% of the US population. The database provides descriptive statistics for people diagnosed with 26 different cancers from 2015-2019 by cancer site, age at diagnosis, sex, and race and ethnicity, all stratified by stage at diagnosis (early, de novo metastatic, and combined). Descriptive characteristics include frequency counts, age-adjusted incidence rates, incidence rate ratios, and 95% CIs. Robustness test results are available in the data query bank by year of diagnosis.

RESULTS

This resource offers insights into distributions of cancer in the US. The AIR Calculator allows users to calculate representative clinical study distributions based on the sponsor-designated study size.

DISCUSSION

The AIR Calculator serves as a valuable resource for planning of clinical studies, but additional data analyses are necessary for a comprehensive understanding at the study level. Comprehensive data collection and alignment across industry are essential to ensure consistent, accurate, and transparent benchmarks in historically underrepresented patient populations and to track progress toward the goal of improving their representation in clinical research.

摘要

背景

2022年签署成为法律的《食品药品综合报告法案》要求行业赞助商在临床研究方案中纳入多样性行动计划。为衡量标准和基准定义可靠的方法对于确保临床试验中历史上代表性不足的患者群体得到充分且一致的体现至关重要。

方法

我们提供了一个推进包容性研究(AIR)计算器、汇总表和数据查询库,以支持制定多样性行动计划的目标设定,并采取措施定义入组标准。AIR计算器使用来自美国癌症统计数据库的数据,该数据库覆盖了100%的美国人口。该数据库提供了2015年至2019年被诊断患有26种不同癌症的人群按癌症部位、诊断年龄、性别、种族和民族分类的描述性统计数据,所有数据均按诊断阶段(早期、初发转移和综合)分层。描述性特征包括频数计数、年龄调整发病率、发病率比和95%置信区间。通过数据查询库可获取按诊断年份分类的稳健性测试结果。

结果

该资源提供了对美国癌症分布情况的见解。AIR计算器允许用户根据赞助商指定的研究规模计算具有代表性的临床研究分布。

讨论

AIR计算器是临床研究规划的宝贵资源,但在研究层面进行全面理解还需要进行额外的数据分析。跨行业的全面数据收集和对齐对于确保历史上代表性不足的患者群体有一致、准确和透明的基准,并跟踪在改善其在临床研究中的代表性目标方面的进展至关重要。